Therefore, the enhanced systemic innate and CD8+ T-cell immune activation, combined with the smaller tumor weights containing fewer immune cells, implies that TLR9 stimulation suppressed prostate immune infiltration or possibly altered the state of tumor-residing immune cells towards an antitumor phenotype. The gene discussed is CD8A; the disease is neoplasm.